Overview

Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)

Status:
WITHDRAWN
Trial end date:
2025-06-23
Target enrollment:
Participant gender:
Summary
This will be a single arm, non-randomized, pre-surgical clinical trial of women with newly diagnosed triple negative breast cancer with high g-H2Ax (gamma H2AX antibodies) comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Virginia G. Kaklamani
Treatments:
Cyclosporine